Trial · NCT01736683
Results by group168
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 168
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate) | Sotatercept 0.1 mg/kg | All participants | 0 | percentage of participants | |
| Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate) | Sotatercept 0.3 mg/kg | All participants | 66.7 | percentage of participants | |
| Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate) | Sotatercept 0.5 mg/kg | All participants | 42.9 | percentage of participants | |
| Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate) | Sotatercept 1.0 mg/kg | All participants | 60.0 | percentage of participants | |
| Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate) | Sotatercept 2.0 mg/kg | All participants | 40.0 | percentage of participants | |
| Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate) | Sotatercept 0.5 mg/kg | NTDE subpopulation | 33.3 | percentage of participants | |
| Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate) | Sotatercept 1.0 mg/kg | NTDE subpopulation | 62.5 | percentage of participants | |
| Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate) | Sotatercept 2.0 mg/kg | NTDE subpopulation | 100 | percentage of participants | |
| Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate) | Sotatercept 0.1 mg/kg | TDE subpopulation | 0 | percentage of participants | |
| Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate) | Sotatercept 0.3 mg/kg | TDE subpopulation | 66.7 | percentage of participants | |
| Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate) | Sotatercept 0.5 mg/kg | TDE subpopulation | 44.4 | percentage of participants | |
| Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate) | Sotatercept 1.0 mg/kg | TDE subpopulation | 59.3 | percentage of participants | |
| Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate) | Sotatercept 2.0 mg/kg | TDE subpopulation | 25.0 | percentage of participants | |
| Time to Erythroid Hematological Improvement (HI-E) Response | Sotatercept 0.3 mg/kg | All participants | 24.0 | Full Range 2 to 44 | days |
| Time to Erythroid Hematological Improvement (HI-E) Response | Sotatercept 0.5 mg/kg | All participants | 1.0 | Full Range 1 to 2 | days |
| Time to Erythroid Hematological Improvement (HI-E) Response | Sotatercept 1.0 mg/kg | All participants | 1.0 | Full Range 1 to 86 | days |
| Time to Erythroid Hematological Improvement (HI-E) Response | Sotatercept 2.0 mg/kg | All participants | 48 | Full Range 9 to 87 | days |
| Time to Erythroid Hematological Improvement (HI-E) Response | Sotatercept 0.5 mg/kg | NTDE subpopulation | 1.0 | Full Range 1 to 1 | days |
| Time to Erythroid Hematological Improvement (HI-E) Response | Sotatercept 1.0 mg/kg | NTDE subpopulation | 1.0 | Full Range 1 to 52 | days |
| Time to Erythroid Hematological Improvement (HI-E) Response | Sotatercept 2.0 mg/kg | NTDE subpopulation | 9.0 | Full Range 9 to 9 | days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01736683/results